Development of immunotherapeutic strategies and vaccines against multidrug resistant C. auris disseminated infection
针对多重耐药耳念珠菌播散性感染的免疫治疗策略和疫苗的开发
基本信息
- 批准号:10433683
- 负责人:
- 金额:$ 22.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-24 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAntibiotic TherapyAntibodiesAntifungal AgentsAntifungal TherapyBloodCD4 Positive T LymphocytesCandidaCandida aurisCell surfaceChronicCombined VaccinesDevelopmentDiseaseDisseminated candidiasisDrug resistanceEpitopesFungal VaccinesFutureGoalsHealthcareHematogenousHospitalsHourHumanImmune responseImmunityImmunocompetentImmunocompromised HostImmunoglobulin GImmunotherapeutic agentIndividualInfectionInterferon Type IILifeMediatingMedicalModelingModernizationMonoclonal AntibodiesMorbidity - disease rateMulti-Drug ResistanceMusOrganPatientsPeptide VaccinesPeptidesPharmaceutical PreparationsPharmacotherapyPhasePlayPopulationPreventative vaccinationPreventive vaccineProductionPublic HealthRecurrenceRegimenResistant candidaRoleSepsisStreamTherapeuticTimeToxic effectTreatment EfficacyTreatment ProtocolsUnited StatesVaccine TherapyVaccinesWorkadaptive immunityeffective therapyfungushigh riskinfancymortalitymouse modelnovel therapeutic interventionpathogenic funguspeptide drugpreventprotective efficacyresponsesynthetic peptidetherapeutic vaccinetherapeutically effectivevaccine candidatevaccine developmentvaccine-induced immunitywork-study
项目摘要
Development of immunotherapeutic strategies and vaccines against multidrug resistant C. auris
disseminated infection
PROJECT SUMMARY
Disseminated candidiasis is a life-threatening disease and remains the third most common bloodstream infection
in hospitalized patients in the United States, with a mortality of 40-60%. Particularly, Candida auris is a multi-
drug resistant, health care-associated fungal pathogen, and has recently emerged as the first fungal pathogen
to cause a global public health threat. There are no effective vaccines for Candida infection or indeed for any
fungi, and significant therapeutic challenges remain. Current anti-Candida treatments are plagued by significant
toxicity and poor efficacy, especially in immunocompromised patients for treating drug resistant Candida species.
Thus, there is a pressing and urgent need for new treatment options. A therapeutic vaccine could bolster both
the protective TH1-mediated immune response and induce protective antibodies, thereby slowing or halting the
progression of dissemination, as well as recurrent in future. Our prior work in mice has demonstrated therapeutic
efficacy of a double peptide vaccine in the acute phase of Candida invasive infection evidenced by significantly
reduction in organ fungal burdens, as well as prolonged survival. This work is a stride towards the development
of a therapeutic C. auris vaccine that seeks to prevent or reduce the mortality in patients infected with C. auris.
This is the first study that demonstrates therapeutic efficacy of a synthetic peptide vaccine in a mouse model of
C. auris disseminated infection.
Our ultimate goals are to develop the first therapeutic double-peptide vaccine composed of peptides that have
high homology in all the medically significant Candida species including C. auris, and to elucidate protective
mechanisms against disseminated candidiasis. In Aim 1, we will seek to investigate whether our double peptide
vaccines could be effective in already established C. auris invasive infection. In Aim 2, we will evaluate the
potential of peptide vaccine candidates serve as immunotherapeutic adjuncts to antibiotic treatment regimens
for C. auris disseminated infection. We will further determine the protective efficacy of the therapeutic peptide
vaccine in immunocompromised mouse models of C. auris invasive infection.
多药耐药念珠菌免疫策略及疫苗的研究进展Auris
播散性感染
项目摘要
播散性念珠菌病是一种危及生命的疾病,仍然是第三大常见的血流感染
在美国的住院患者中,死亡率为40- 60%。特别是,耳念珠菌是一种多-
耐药,卫生保健相关的真菌病原体,最近出现的第一个真菌病原体
造成全球公共卫生威胁目前还没有有效的疫苗来治疗念珠菌感染,
真菌,并且仍然存在显著的治疗挑战。目前的抗念珠菌治疗受到显著的
毒性和疗效差,特别是在免疫功能低下的患者中用于治疗耐药念珠菌属。
因此,迫切需要新的治疗选择。一种治疗性疫苗可以同时支持
保护性TH 1介导的免疫应答,并诱导保护性抗体,从而减缓或停止
传播的进展,以及在未来经常性。我们之前在小鼠身上的研究已经证明了
双肽疫苗在念珠菌侵袭性感染的急性期的有效性被显著地证实,
减少器官真菌负担,以及延长生存期。这项工作是向发展迈出的一大步
一个治疗C。auris疫苗旨在预防或降低感染C.耳。
这是第一项证明合成肽疫苗在小鼠模型中的治疗效果的研究。
C.耳播散性感染。
我们的最终目标是开发第一个治疗性双肽疫苗,
在所有具有医学意义的念珠菌属物种中,包括C.耳,并阐明保护
抗播散性念珠菌病的机制。在目标1中,我们将寻求研究我们的双肽是否
疫苗在已经建立的C.耳侵袭性感染。在目标2中,我们将评估
肽疫苗候选物作为抗生素治疗方案的免疫抑制剂的潜力
梭耳播散性感染。我们将进一步确定治疗肽的保护功效
疫苗免疫功能低下的小鼠模型的C.耳侵袭性感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hong Xin其他文献
Hong Xin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hong Xin', 18)}}的其他基金
Development of immunotherapeutic strategies and vaccines against multidrug resistant C. auris disseminated infection
针对多重耐药耳念珠菌播散性感染的免疫治疗策略和疫苗的开发
- 批准号:
10554417 - 财政年份:2022
- 资助金额:
$ 22.05万 - 项目类别:
Design of a mimotope-peptide based double epitope vaccine against candidiasis
基于模拟表位肽的抗念珠菌病双表位疫苗的设计
- 批准号:
9117145 - 财政年份:2015
- 资助金额:
$ 22.05万 - 项目类别:
Design of a mimotope-peptide based double epitope vaccine against candidiasis
基于模拟表位肽的抗念珠菌病双表位疫苗的设计
- 批准号:
9093696 - 财政年份:2015
- 资助金额:
$ 22.05万 - 项目类别:
Synthetic glycopeptide vaccines that enhance resistance to candidiasis
增强念珠菌病抵抗力的合成糖肽疫苗
- 批准号:
8571542 - 财政年份:2013
- 资助金额:
$ 22.05万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.05万 - 项目类别:
Research Grant